Celyad Oncology SA · EURONEXT:CYAD

Celyad Oncology SA — Fact Sheet (May 2022)

2 slides from Celyad Oncology SA's fact sheet, May 4, 2022

  1. Slide 1: IMMUNICY-1 Dose-Escalation Clinical Study CYAD-211

    IMMUNICY-1 Dose-Escalation Clinical Study CYAD-211 Study Overview Primary Objectives • Three cohorts to define the recommended dose • To determine the recommended dose of CYAD-211 after a nonmyeloablative • Dose levels to be investigated: 3x10⁷, 1x10⁸ and preconditioning chemotherapy for patients wi

  2. Slide 2: CYAD-211 Overview: Non-Gene Edited Allogeneic CAR T

    IMMUNICY-1 Dose-Escalation Clinical Study CYAD-211 CYAD-211 Overview Non-Gene Edited Allogeneic CAR T • Second generation CAR targeting B Cell Maturation Antigen (BCMA) • Truncated CD34 selection marker • Single short hairpin RNA (shRNA) interferes with CD3ζ component of the T cell receptor (TCR) co

Celyad Oncology — Fact Sheet (May 2022) on 6ix